Alessandro Natoni | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
PSGL-1 decorated with sialyl Lewisa/x promotes high affinity binding of myeloma cells to P-selectin but is dispensable for E-selectin engagement	SCIENTIFIC REPORTS	2024
Sialylation regulates migration in chronic lymphocytic leukemia	HAEMATOLOGICA	2023
Sialofucosylation Enables Platelet Binding to Myeloma Cells via P-Selectin and Suppresses NK Cell-Mediated Cytotoxicity	CANCERS	2023
The Role of the Microenvironment and Cell Adhesion Molecules in Chronic Lymphocytic Leukemia	CANCERS	2023
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment	CLINICAL LYMPHOMA MYELOMA & LEUKEMIA	2022
Chronic nitric oxide exposure induces prostate cell carcinogenesis, involving genetic instability and a pro-tumorigenic secretory phenotype	NITRIC OXIDE	2022
Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses	BLOOD ADVANCES	2022
Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis	CYTOMETRY. PART B, CLINICAL CYTOMETRY	2022
P861: SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY	HEMASPHERE	2022
Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis	ONCOIMMUNOLOGY	2021
Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment	BLOOD	2021
The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide	CANCER IMMUNOLOGY, IMMUNOTHERAPY	2020
Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14)	HAEMATOLOGICA	2020
Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model	HAEMATOLOGICA	2020
Targeted Approaches to Inhibit Sialylation of Multiple Myeloma in the Bone Marrow Microenvironment		2019
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study		2019
Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor		2019
Hypersialylation protects Myeloma cells from NK cell mediated killing and this can be overcome by targeted desialylation using a sialyltransferase inhibitor		2019
CD38(low) Natural Killer Cells Transiently Expressing CD16(F158V) m-RNA Potentiates the Therapeutic Activity of Daratumumab Against Multiple Myeloma with Minimal Effector NK Cell Fratricide	BLOOD	2018
Inhibition of Sialylation Impairs Adhesion on Madcam-1 and E-Selectin and Sensitize Multiple Myeloma Cells to Bortezomib in a Xenograft Mouse Model	BLOOD	2018